Licochalcone A Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 370

Clinical Trials

Multiple clinical trials have evaluated the therapeutic application of Licochalcone A, primarily focusing on dermatological and oncological conditions such as acne vulgaris and squamous cell carcinoma. Ranging from Phase 1 and Phase 3 evaluations to unassigned phase classifications, these completed studies investigated topical regimens and adjunctive chemotherapy protocols. Sponsorship for these investigations was provided by academic and corporate entities, including Mahidol University, Cairo University, and Beiersdorf.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292822	COMPLETED	Squamous Cell Carcinoma	Cairo University	2021-02-15	PHASE1
NCT04002024	COMPLETED	Acne Vulgaris; Acne	Mahidol University	2019-06-01
NCT04002024	Completed	Acne Vulgaris\|Acne	Mahidol University\|Beiersdorf	2019-06-01	Not Applicable
NCT02173054	COMPLETED	Acne	Mahidol University	2014-07	PHASE3

(data from https://clinicaltrials.gov, updated on 2024-06-20)

Check the Licochalcone A product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Licochalcone A selectively modulates estrogenic receptors and inflammatory pathways, suppressing downstream pro-inflammatory cytokine secretion and oncogenic signal transduction. This targeted biochemical inhibition reduces cellular proliferation and mitigates localized tissue inflammation, demonstrating therapeutic potential in clinical applications targeting acne vulgaris and squamous cell carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).